# SBRT as a Vaccination for Metastatic Melanoma

> **NCT04042506** · PHASE2 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT04042506
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11-26
- **Primary completion:** 2019-11-26
- **Final completion:** 2021-01-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to enroll patients in this study
- **Last updated:** 2021-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04042506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04042506, "SBRT as a Vaccination for Metastatic Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04042506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*